Erythromycin‐Associated Cholestatic Hepatitis
| Autor: | Alan D. Dean, David Henry, Laura E. Derby, Hershel Jick |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent medicine.medical_treatment Erythromycin Gastroenterology Cohort Studies Internal medicine medicine Humans Medical prescription Child Aged Retrospective Studies Aged 80 and over Hepatitis Chemotherapy Cholestasis business.industry Retrospective cohort study General Medicine Middle Aged medicine.disease Confidence interval Cholestatic hepatitis Female Chemical and Drug Induced Liver Injury business medicine.drug Cohort study |
| Zdroj: | Medical Journal of Australia. 158:600-602 |
| ISSN: | 1326-5377 0025-729X |
| DOI: | 10.5694/j.1326-5377.1993.tb137625.x |
| Popis: | Objective To estimate the risk of cholestatic hepatitis of uncertain origin in patients who had recently received erythromycin, a drug which is known to cause this disorder. Design A retrospective cohort study using data automatically recorded on general practitioners' office computers. Setting Some 600 general practices in the United Kingdom. Subjects 366,064 people who received erythromycin. Main outcome measure Clinically documented cholestatic hepatitis of uncertain origin diagnosed 1-45 days after a prescription for erythromycin. Results There were 13 cases of cholestatic hepatitis of uncertain origin diagnosed within 45 days of receiving erythromycin which were either characteristic of or consistent with a syndrome previously described as being associated with this drug. Conclusion The risk of cholestatic jaundice associated with erythromycin is estimated to be in the range of 3.6 per 100,000 users (95% confidence interval, 1.9-6.1). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text